

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/616,094 07/08/2003		Francis J. Martin	5325-0151,31N2	1352
27777 75	590 05/19/2004		EXAMINER	
PHILIP S. JOHNSON JOHNSON & JOHNSON			KATCHEVES, KONSTANTINA T	
ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933-7003			ART UNIT	PAPER NUMBER
			1636	
			DATE MAIL ED: 05/19/2007	•

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	
		10/616,094	MARTIN ET AL.	
Office Action Summary		Examiner	Art Unit	
		Konstantina Katcheves	1636	
The MAILING DATE of the Period for Reply	his communication a	appears on the cover sheet with	the correspondence address	
 Failure to reply within the set or extended 	COMMUNICATION or the provisions of 37 CFR late of this communication. ess than thirty (30) days, a the maximum statutory peri d period for reply will, by sta n three months after the ma	N. 1.136(a). In no event, however, may a repreply within the statutory minimum of thirty od will apply and will expire SIX (6) MONTI	oly be timely filed (30) days will be considered timely. HS from the mailing date of this communication. NDONED (35 U.S.C. § 133).	
Status				
1) Responsive to communic	cation(s) filed on 18	November 2003.		
2a) This action is FINAL .		his action is non-final.		
3) Since this application is i	<i>'</i> —		rs, prosecution as to the merits is	
		r <i>Ex parte Quayle</i> , 1935 C.D.		
Disposition of Claims				
4)⊠ Claim(s) <u>1-3,5-15 and 17</u>	' is/are pending in t	ne application.		
4a) Of the above claim(s)		• •		
5) Claim(s) is/are allo				
6) Claim(s) is/are rej	ected.			
7) Claim(s) is/are obj	ected to.			
8)⊠ Claim(s) <u>1-3,5-15 and 17</u>	are subject to rest	riction and/or election requiren	nent.	
Application Papers				
9)☐ The specification is object	ted to by the Exami	ner.		
10)☐ The drawing(s) filed on _	is/are: a)□ a	ccepted or b) objected to by	the Examiner.	
Applicant may not request the	hat any objection to th	ne drawing(s) be held in abeyance	e. See 37 CFR 1.85(a).	
Replacement drawing sheet	t(s) including the corre	ection is required if the drawing(s)	is objected to. See 37 CFR 1.121(d).	
11) The oath or declaration is	objected to by the	Examiner. Note the attached (Office Action or form PTO-152.	
Priority under 35 U.S.C. § 119				
12) Acknowledgment is made a) All b) Some * c) □		gn priority under 35 U.S.C. § 1	19(a)-(d) or (f).	
1. Certified copies of	the priority docume	nts have been received.		
		nts have been received in App	olication No	
		iority documents have been re		
application from the	e International Bure	au (PCT Rule 17.2(a)).	-	
* See the attached detailed (Office action for a lis	st of the certified copies not re	ceived.	
Attachment(s)		_		
 Notice of References Cited (PTO-892 Notice of Draftsperson's Patent Drawi 			nmary (PTO-413)	
 Information Disclosure Statement(s) (Mail Date mal Patent Application (PTO-152)	
Paper No(s)/Mail Date	Si i i Si	6) Other:		

U.S. Patent and Trademark Office PTOL-326 (Rev. 1-04) Application/Control Number: 10/616,094

Art Unit: 1636

DETAILED ACTION

Claims 1-3, 5-15 and 17 are pending in the present application.

Election/Restrictions

This application contains claims directed to the following patentably distinct species of the claimed invention: hydrophilic polymers as in claim 5 and affinity moieties of claim 11. The hydrophilic polymers of claim 5 include: polyvinylpyrrolidone, polyvinylmethylether, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyloxazoline, polyhydroxypropylmethacllamide, polymethacrylamide, polydimethyl-acrylamide, polyhydroxypropylmethacllate, polyhydroxyethylacrylate, hydroxymethylcellulose, hydroxyethylcellulose, polyethyleneglycol, and polyaspadamide. The affinity moieties of claim 11 include: CD4 glycoprotein, a polysaccharide which binds to endothelial leukocyte adhesion molecule (ELAM); polymyxin B or polymyxin B decapeptide, and a peptide.

These species are patentably distinct and so diverse in chemical structure that a reference anticipating one of the species would not anticipate or render obvious to other species. Thus, the stated species are capable or supporting separate patents.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-3, 5-10 and 12-17 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable

Application/Control Number: 10/616,094

Art Unit: 1636

thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1636

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Konstantina Katcheves whose telephone number is (571) 272-0768. The examiner can normally be reached on Monday, Tuesday, Thursday and Friday 7:30 to 5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Remy Yucel, Ph.D. can be reached on (571) 272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Konstantina Katcheves televes Group Art Unit: 1636